Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Quentin30 is a pathological prevaricator.

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Sep 17, 2024 7:41pm

58 Views

Post# 36228187

RE:RE:RE:RE:RE:Quentin30 is a pathological prevaricator.

Yes ONCY has affirmed their pursuit of an Accelerated Approval pathway after the release of the mature OS. I suggest you get up to speed on the current information before spewing your nonsense. ONCY has conducted 2 Phase 2 trials (IND-213 and Bracelet-1) in which the IND-213 results were replicated in Bracelet-1 along with confirmation of 3 surrogate endpoints with the FDA agreeing to PFS as the primary endpoint in the planned 180-200 patient Phase 2b->Phase3->Confirmatory clinical trial.

<< Previous

Bullboard Posts

Next >>

Nextech CEO provides company update on Amazon deal and more